November 5, 2021 Texas HIV Medication Advisory Committee
»
Item 1 - Call to Order and Welcome – Natalie Vanek, M.D., Committee Chair
Item 1
Call to Order and Welcome – Natalie Vanek, M.D., Committee Chair
»
Item 2 - Logistical Announcement and Roll Call – Sallie Allen, Advisory Committee Coordination Office, HHSC
Item 2
Logistical Announcement and Roll Call – Sallie Allen, Advisory Committee Coordination Office, HHSC
»
Item 3 - Consideration of July 30, 2021, Meeting Minutes (Vote Required) – Sallie Allen, Advisory Committee Coordination Office, HHSC
Item 3
Consideration of July 30, 2021, Meeting Minutes (Vote Required) – Sallie Allen, Advisory Committee Coordination Office, HHSC
»
Item 4 - Department of State Health Services updates – Imelda Garcia, MPH Associate Commissioner of Laboratory and Infectious Disease Services (LIDS)
a. Staffing Updates
b. HIV Budget report
c. September 29, 2021 Partnership meeting summary update
Item 4
Department of State Health Services updates – Imelda Garcia, MPH Associate Commissioner of Laboratory and Infectious Disease Services (LIDS)a. Staffing Updates
b. HIV Budget report
c. September 29, 2021 Partnership meeting summary update
»
Item 5 - THMP Update - Rachel Sanor, THMP Manager
a. MAC appointment process
b. THMP - Projections and Demographic information
c. THMP backlog
d. Spend down suspension
e. 90-day supply analysis
Item 5
THMP Update - Rachel Sanor, THMP Managera. MAC appointment process
b. THMP - Projections and Demographic information
c. THMP backlog
d. Spend down suspension
e. 90-day supply analysis
»
Item 6 - Pharmacy Annual Inventory Update & Report – Joshua Hutchison, Pharmacy Director
Item 6
Pharmacy Annual Inventory Update & Report – Joshua Hutchison, Pharmacy Director
»
Item 8 - Subcommittee reports
a.
Governance/Data – Nancy Miertschin
b.
Eligibility – Frank Rosas
c.
Formulary Sub-committee – Natalie Vanek, M.D.
Impact of suspended medications
Recommendation to approve pediatric medications
Raltegravir 25mg (new dosage)
Tivicay (new dosage)
Item 8
Subcommittee reportsa.
Governance/Data – Nancy Miertschin
b.
Eligibility – Frank Rosas
c.
Formulary Sub-committee – Natalie Vanek, M.D.
Impact of suspended medications
Recommendation to approve pediatric medications
Raltegravir 25mg (new dosage)
Tivicay (new dosage)
»
Item 9 (Part 1 of 2) - Committee to vote on addition of Raltegravir 25 mg and Tivicay PD to THMP formulary (Vote Required)
Item 9 (Part 1 of 2)
Committee to vote on addition of Raltegravir 25 mg and Tivicay PD to THMP formulary (Vote Required)
»
Item 10 - Public Comment – Sallie Allen, Advisory Committee Coordination Office, HHSC
Item 10
Public Comment – Sallie Allen, Advisory Committee Coordination Office, HHSC
»
Item 9 (Part 2 of 2) - Committee to vote on addition of Raltegravir 25 mg and Tivicay PD to THMP formulary (Vote Required)
Item 9 (Part 2 of 2)
Committee to vote on addition of Raltegravir 25 mg and Tivicay PD to THMP formulary (Vote Required)
»
Items 11 & 12 - 11. Action items and agenda topics for next scheduled meeting: January 22, 2022– Natalie Vanek, M.D., Committee Chair
12. Adjourn – Natalie Vanek, M.D., Committee Chair
Items 11 & 12
11. Action items and agenda topics for next scheduled meeting: January 22, 2022– Natalie Vanek, M.D., Committee Chair12. Adjourn – Natalie Vanek, M.D., Committee Chair
